• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Viemed Healthcare Inc.

    2/2/24 2:18:06 PM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care
    Get the next $VMD alert in real time by email
    SC 13G 1 ca92663r1055_020224.txt ca92663r1055_020224.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) VIEMED HEALTHCARE, INC. -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) BFFK5Z9 -------------------------------------------------------- (SEDOL Number) December 31, 2023 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). SEDOL No. BFFK5Z9 (1)Names of reporting persons. BlackRock, Inc. (2) Check the appropriate box if a member of a group (a) [ ] (b) [X] (3) SEC use only (4) Citizenship or place of organization Delaware Number of shares beneficially owned by each reporting person with: (5) Sole voting power 2074522 (6) Shared voting power 0 (7) Sole dispositive power 2129167 (8) Shared dispositive power 0 (9) Aggregate amount beneficially owned by each reporting person 2129167 (10) Check if the aggregate amount in Row (9) excludes certain shares (11) Percent of class represented by amount in Row 9 5.6% (12) Type of reporting person HC Item 1. Item 1(a) Name of issuer: ----------------------------------------------------------------------- VIEMED HEALTHCARE, INC. Item 1(b) Address of issuer's principal executive offices: ----------------------------------------------------------------------- 625 E. KALISTE SALOOM RD. LAFAYETTE LA 70508 Item 2. 2(a) Name of person filing: ---------------------------------------------------------------------- BlackRock, Inc. 2(b) Address or principal business office or, if none, residence: ----------------------------------------------------------------------- BlackRock, Inc. 50 Hudson Yards New York, NY 10001 2(c) Citizenship: -------------------------------------------------------------------- See Item 4 of Cover Page 2(d) Title of class of securities: ------------------------------------------------------------------- Common Stock 2(e) SEDOL No.: See Cover Page Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: [ ] Broker or dealer registered under Section 15 of the Act; [ ] Bank as defined in Section 3(a)(6) of the Act; [ ] Insurance company as defined in Section 3(a)(19) of the Act; [ ] Investment company registered under Section 8 of the Investment Company Act of 1940; [ ] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); [ ] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); [X] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940; [ ] A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J); [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Item 4. Ownership Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. Amount beneficially owned: 2129167 Percent of class 5.6% Number of shares as to which such person has: Sole power to vote or to direct the vote 2074522 Shared power to vote or to direct the vote 0 Sole power to dispose or to direct the disposition of 2129167 Shared power to dispose or to direct the disposition of 0 Item 5. Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ ]. Item 6. Ownership of More than 5 Percent on Behalf of Another Person If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of VIEMED HEALTHCARE, INC.. No one person's interest in the common stock of VIEMED HEALTHCARE, INC. is more than five percent of the total outstanding common shares. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. See Exhibit A Item 8. Identification and Classification of Members of the Group If a group has filed this schedule pursuant to Rule 13d-1(b)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group. Item 9. Notice of Dissolution of Group Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5. Item 10. Certifications By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: February 2, 2024 BlackRock, Inc. Signature: Spencer Fleming ------------------------------------------- Name/Title Attorney-In-Fact The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature. Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001). Exhibit A Subsidiary BlackRock Advisors, LLC Aperio Group, LLC BlackRock Asset Management Canada Limited BlackRock Fund Advisors BlackRock Institutional Trust Company, National Association BlackRock Financial Management, Inc. BlackRock Investment Management, LLC *Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Exhibit B POWER OF ATTORNEY The undersigned, BlackRock, Inc., a corporation duly organized under the laws of the State of Delaware, United States (the "Company"), does hereby make, constitute and appoint each of Eric Andruczyk, Richard Cundiff, R. Andrew Dickson, III, Spencer Fleming, Daniel Goldmintz, Laura Hildner, Elizabeth Kogut, David Maryles, Christopher Meade, Una Neary, Charles Park, Daniel Riemer, David Rothenberg and Brenda Schulz, acting severally, as its true and lawful attorneys-in-fact, for the purpose of, from time to time, executing, in its name and on its behalf and on behalf of its direct and indirect subsidiaries, any and all documents, certificates, instruments, statements, filings, agreements and amendments (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, including, without limitation, Schedules 13D and 13G and Forms 3, 4, 5, 13F and 13H and any amendments to any of the foregoing as may be required to be filed with the Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental or regulatory authority or other person, and giving and granting to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully and to all intents and purposes as the Company and/or its direct and indirect subsidiaries, as applicable, might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall expressly revoke the power of attorney dated 2nd day of January, 2019 in respect of the subject matter hereof, shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates. IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be executed as of this 30th day of April, 2023. BlackRock, Inc. By: /s/ R. Andrew Dickson, III Name: R. Andrew Dickson, III Title: Corporate Secretary
    Get the next $VMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VMD

    DatePrice TargetRatingAnalyst
    11/3/2021$13.00 → $9.00Outperform
    RBC Capital
    More analyst ratings

    $VMD
    SEC Filings

    See more
    • Viemed Healthcare Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - VIEMED HEALTHCARE, INC. (0001729149) (Filer)

      6/5/25 5:15:49 PM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 10-Q filed by Viemed Healthcare Inc.

      10-Q - VIEMED HEALTHCARE, INC. (0001729149) (Filer)

      5/7/25 4:50:18 PM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • Viemed Healthcare Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - VIEMED HEALTHCARE, INC. (0001729149) (Filer)

      5/7/25 4:47:49 PM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care

    $VMD
    Leadership Updates

    Live Leadership Updates

    See more
    • Viemed Executes Diversification Strategy With $26 Million Acquisition of Home Equipment Provider in Illinois

      LAFAYETTE, La., May 06, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, announced that it has entered into a definitive agreement to acquire Illinois-based Lehan's Medical Equipment ("Lehan"), a healthcare company offering home medical equipment with specialties in respiratory care and women's health. "Operating for nearly 80 years, Lehan has established a well-deserved reputation for its expertise in home medical equipment with a particular emphasis on women's health and a deep commitment to community engagement," said Viemed Chief

      5/6/25 8:30:00 AM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • Viemed Announces Acquisition of Majority Interest in HomeMed, Forging Partnership With East Alabama Health

      LAFAYETTE, La., April 02, 2024 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced the finalization of its strategic partnership with East Alabama Health ("EAH"), providing Viemed with the controlling interest of East Alabama HomeMed, LLC ("HomeMed"). HomeMed provides home medical equipment services to patients within the EAH network as well as those in the surrounding areas of Eastern Alabama. "We are thrilled to join forces with the exceptional team at East Alabama Health to deliver best-in-class home medical services to their patients and expand Home

      4/2/24 9:00:00 AM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • Viemed Healthcare Announces Voting Results From Its Annual General Meeting of Shareholders

      LAFAYETTE, La., June 13, 2023 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD, TSX:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, today announced the voting results from its annual general meeting of shareholders held on June 13, 2023 (the "Meeting") in Lafayette, Louisiana. The total number of shares represented in person or by proxy at the Meeting was 27,309,147, representing 71.33% of the total issued and outstanding shares in the capital of the Company. Election of Directors The eight candidates nominated for election to the Company's Board of Directors (the "Board") and listed in the Company's m

      6/13/23 5:00:00 PM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care

    $VMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Viemed Healthcare Inc. (Amendment)

      SC 13D/A - VIEMED HEALTHCARE, INC. (0001729149) (Subject)

      2/15/24 9:27:58 AM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13G/A filed by Viemed Healthcare Inc. (Amendment)

      SC 13G/A - VIEMED HEALTHCARE, INC. (0001729149) (Subject)

      2/15/24 9:27:32 AM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13G filed by Viemed Healthcare Inc.

      SC 13G - VIEMED HEALTHCARE, INC. (0001729149) (Subject)

      2/14/24 4:51:42 PM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care

    $VMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Smokoff Timothy sold $91,364 worth of shares (11,865 units at $7.70), decreasing direct ownership by 13% to 79,786 units (SEC Form 4)

      4 - VIEMED HEALTHCARE, INC. (0001729149) (Issuer)

      3/17/25 4:42:59 PM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • Chief Operating Officer Zehnder William Todd converted options into 35,791 shares, covered exercise/tax liability with 8,147 shares and returned $74,089 worth of shares to the company (8,948 units at $8.28), increasing direct ownership by 7% to 273,973 units (SEC Form 4)

      4 - VIEMED HEALTHCARE, INC. (0001729149) (Issuer)

      1/31/25 3:28:06 PM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • Chief Financial Officer Fitzgerald Trae converted options into 13,060 shares, covered exercise/tax liability with 2,962 shares and returned $27,034 worth of shares to the company (3,265 units at $8.28), increasing direct ownership by 9% to 82,994 units (SEC Form 4)

      4 - VIEMED HEALTHCARE, INC. (0001729149) (Issuer)

      1/31/25 3:27:56 PM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care

    $VMD
    Financials

    Live finance-specific insights

    See more
    • Viemed Healthcare Announces First Quarter 2025 Financial Results

      LAFAYETTE, La., May 07, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three months ended March 31, 2025, and updated guidance for the full year ending December 31, 2025. Operational highlights (all dollar amounts are USD): Net revenues for the quarter ended March 31, 2025 were $59.1 million, representing an increase of $8.5 million, or 17%, over net revenues reported for the comparable quarter ended March 31, 2024. Net income attributable to Viemed for t

      5/7/25 4:45:00 PM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • Viemed Healthcare Announces First Quarter 2025 Earnings Conference Call Details

      LAFAYETTE, La., April 22, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, today announced that it will host its First Quarter 2025 Earnings Conference Call on Thursday, May 8, 2025, at 11:00 a.m. EDT. Interested parties may participate in the call by dialing: (866) 682-6100 (US Toll-Free) +1 (862) 298-0702 (International) Live Audio Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=0dOJVhdb Following the live call, a replay will be available in the Investor Relations section of the Company's website at www.viemed.com. ABOUT VIE

      4/22/25 4:30:00 PM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • Viemed Healthcare Announces Record 2024 Financial Results

      LAFAYETTE, La., March 10, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three months and year ended December 31, 2024, and issued its guidance for the full year ending December 31, 2025. Fourth Quarter and Full Year Operational Highlights (all dollar amounts are USD): Net revenues for the quarter ended December 31, 2024 reached a new Company record of $60.7 million representing an increase of $10.0 million, or 20%, over net revenues reported for the comparable quarter ended Decembe

      3/10/25 5:00:00 PM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care

    $VMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Heltz Sabrina bought $19,977 worth of shares (2,820 units at $7.08), increasing direct ownership by 7% to 41,040 units (SEC Form 4)

      4 - VIEMED HEALTHCARE, INC. (0001729149) (Issuer)

      5/14/24 5:25:11 PM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care

    $VMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $VMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Viemed Healthcare to Present and Host 1x1 Investor Meetings at the 15th Annual East Coast Ideas Investor Conference on June 11th in New York

      LAFAYETTE, La., June 03, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, today announced it will present at the East Coast IDEAS Investor Conference on Wednesday June 11, 2025 at The Westin Times Square in New York, NY. Viemed's presentation is scheduled to begin at 11:30am ET. The presentation is webcast and can be accessed through the conference host's main website: https://www.threepartadvisors.com/east-coast and in the investor relations section of the Company's website: http://viemed.com/investors. ABOUT VIEMED HEALTHCARE, INC. Viemed is an

      6/3/25 8:00:00 AM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • Viemed Healthcare Announces First Quarter 2025 Financial Results

      LAFAYETTE, La., May 07, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three months ended March 31, 2025, and updated guidance for the full year ending December 31, 2025. Operational highlights (all dollar amounts are USD): Net revenues for the quarter ended March 31, 2025 were $59.1 million, representing an increase of $8.5 million, or 17%, over net revenues reported for the comparable quarter ended March 31, 2024. Net income attributable to Viemed for t

      5/7/25 4:45:00 PM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • Viemed Executes Diversification Strategy With $26 Million Acquisition of Home Equipment Provider in Illinois

      LAFAYETTE, La., May 06, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, announced that it has entered into a definitive agreement to acquire Illinois-based Lehan's Medical Equipment ("Lehan"), a healthcare company offering home medical equipment with specialties in respiratory care and women's health. "Operating for nearly 80 years, Lehan has established a well-deserved reputation for its expertise in home medical equipment with a particular emphasis on women's health and a deep commitment to community engagement," said Viemed Chief

      5/6/25 8:30:00 AM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • RBC Capital reiterated coverage on Viemed Healthcare with a new price target

      RBC Capital reiterated coverage of Viemed Healthcare with a rating of Outperform and set a new price target of $9.00 from $13.00 previously

      11/3/21 9:01:34 AM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • Royal Bank of Canada initiated coverage on Viemed Healthcare with a new price target

      Royal Bank of Canada initiated coverage of Viemed Healthcare with a rating of Outperform and set a new price target of $13.00

      3/11/21 8:08:09 AM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care
    • RBC Capital initiated coverage on Viemed Healthcare with a new price target

      RBC Capital initiated coverage of Viemed Healthcare with a rating of Outperform and set a new price target of $13.00

      3/5/21 8:11:16 AM ET
      $VMD
      Misc Health and Biotechnology Services
      Health Care